The phase 1/2 clinical trial BP41072 is evaluating the safety and preliminary efficacy of englumafusp alfa—a novel investigational therapy—when administered in combination with the CD20×CD3 bispecific antibody glofitamab for patients …
Tag:
Infectious Diseases
-
-
Gene therapy for inherited blood disorders has moved from experimental uncertainty to a new standard of reliable clinical care, driven by the success of ex vivo CRISPR-based treatments. According to …
-
RAG-17 Investigational Therapy: Clinical Progress in SOD1-ALS Treatment Researchers are currently evaluating RAG-17, an investigational oligonucleotide therapy designed to target the SOD1 gene, in a clinical trial for patients with …
-
The STARD-AI reporting guideline provides a standardized framework for researchers to improve the transparency and reproducibility of diagnostic accuracy studies involving artificial intelligence. Published in Nature Medicine, the initiative addresses …
-
Targeting GNAQ/GNA11 Mutations: Progress in Metastatic Uveal Melanoma Treatment Researchers are evaluating the antibody-drug conjugate (ADC) DYP688 as a potential treatment for patients with GNAQ/GNA11-mutant metastatic uveal melanoma or other …
-
Chronic sleep deprivation and the prevalence of sleep disorders have emerged as significant public health challenges, with the Centers for Disease Control and Prevention (CDC) reporting that one in three …
-
Advancements in Gene Therapy for Congenital Deafness: Sequential Bilateral Treatment Recent clinical progress in gene therapy for genetic hearing loss demonstrates that sequential bilateral treatment is both safe and effective, …
-
Human papillomavirus (HPV) has emerged as a primary driver of oropharyngeal squamous cell carcinoma (OPSCC), fundamentally shifting how clinicians approach head and neck cancer. According to the Centers for Disease …
-
2024 McDonald Criteria Revisions: Advances in Multiple Sclerosis Diagnosis The 2024 revisions to the McDonald criteria represent a significant evolution in the diagnosis of multiple sclerosis (MS), aiming to facilitate …
-
Clinical Trial NCT02658981: Investigating Relatlimab for Recurrent Glioblastoma A multicenter, phase 1 clinical trial (NCT02658981), conducted under the NCI Adult Brain Tumor Consortium (ABTC), evaluated the safety and immunological impact …
Newer Posts